Winand N. M. Dinjens

Winand N. M. Dinjens

Auto-generated profile, based on publicly available information

Winand N. M. Dinjens

Department of Pathology, Josephine Nefkens Institute, Erasmus MC, University Medical Center, Rotterdam, The Netherlands

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 August 2022 in Journal of Clinical Oncology
Verified
Journal Article
Open access
ALAndrew B. Lassman
Andrew B. Lassman
KHKhê Hoang-Xuan
Khê Hoang-Xuan
MPMei-Yin C. Polley
Mei-Yin C. Polley
ABAlba A. Brandes
Alba A. Brandes
JCJ. Gregory Cairncross
J. Gregory Cairncross
MBMartin J. Van Den Bent
Martin J. Van Den Bent
Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the basis of the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported. Anaplastic oligodendroglial tumors (AOTs) are chemotherapy-sensitive brain tumors. We report the final very long-term survival results from European Organization for the Research and Treatment of Cancer 26951 and Radiation Therapy Oncology Group 9402 phase III trials initiated in 1990s, which both studied radiotherapy with/without neo/adjuvant procarbazine, lomustine, and vincristine (PCV) for newly diagnosed anaplastic oligodendroglial tumors. The median follow-up duration in both was 18-19 years. For European Organization for the Research and Treatment of Cancer 26951, median, 14-year, and probable 20-year overall survival rates without versus with PCV were 2.6 years, 13.4%, and 10.1% versus 3.5 years, 25.1%, and 16.8% (N = 368 overall; hazard ratio [HR] 0.78; 95% CI, 0.63 to 0.98; P = .033), with 1p19q codeletion 9.3 years, 26.2%, and 13.6% versus 14.2 years, 51.0%, and 37.1% (n = 80; HR 0.60; 95% CI, 0.35 to 1.03; P = .063), respectively. For Radiation Therapy Oncology Group 9402, analogous results were 4.8 years, 16.5%, and 11.2% versus 4.8 years, 29.1%, and 24.6% (N = 289 overall; HR 0.79; 95% CI, 0.61 to 1.03; P = .08), with codeletion 7.3 years, 25.0%, and 14.9% versus 13.2 years, 46.1%, and 37% (n = 125; HR 0.61; 95% CI, 0.40 to 0.94; P = .02), respectively. With that, the studies show similar long-term survival even without tumor recurrence in a significant proportion of patients after first-line treatment with radiotherapy/PCV.

2 October 2020 in International Journal of Cancer
Verified
Journal Article
Open access
PDF file
TDThomas van Doeveren
Thomas van Doeveren
JNJose A. Nakauma‐Gonzalez
Jose A. Nakauma‐Gonzalez
Andrew MasonAndrew Mason
Andrew Mason
GLGeert J. L. H. van Leenders
Geert J. L. H. van Leenders
Tahlita ZuiverloonTahlita Zuiverloon
Tahlita Zuiverloon
JBJoost L. Boormans
Joost L. Boormans
The risk of developing urothelial carcinoma of the bladder (UCB) in patients treated by radical nephroureterectomy (RNU) for an upper urinary tract urothelial carcinoma (UTUC) is 22% to 47% in the 2 years after surgery. Subject of debate remains whether UTUC and the subsequent UCB are clonally related or represent separate origins. To investigate the clonal relationship between both entities, we performed targeted DNA sequencing of a panel of 41 genes on matched normal and tumor tissue of 15 primary UTUC patients treated by RNU who later developed 19 UCBs. Based on the detected tumor‐specific DNA aberrations, the paired UTUC and UCB(s) of 11 patients (73.3%) showed a clonal relation, whereas in four patients the molecular results did not indicate a clear clonal relationship. Our results support the hypothesis that UCBs following a primary surgically resected UTUC are predominantly clonally derived recurrences and not separate entities.

10 November 2008 in The Journal of Pathology
Verified
Journal Article
Closed access
PDF file
EKEsther Korpershoek
Esther Korpershoek
ALAnne Jm Loonen
Anne Jm Loonen
SCSuzanne Corvers
Suzanne Corvers
FNFrancien H van Nederveen
Francien H van Nederveen
JJJos Jonkers
Jos Jonkers
Ronald de KrijgerRonald de Krijger
Ronald de Krijger

12 November 2011 in Genes, Chromosomes and Cancer
Verified
Journal Article
Closed access
PDF file
JBJurjen Boonstra
Jurjen Boonstra
RMRonald van Marion
Ronald van Marion
HDHannie J. C. W. Douben
Hannie J. C. W. Douben
JLJerry S. Lanchbury
Jerry S. Lanchbury
KTKirsten M. Timms
Kirsten M. Timms
WDWinand N. M. Dinjens
Winand N. M. Dinjens

1 September 2014 in Neuro-Oncology
Verified
Journal Article
Open access
WTWalter Taal
Walter Taal
HOH. M. Oosterkamp
H. M. Oosterkamp
AWAnnemiek Walenkamp
Annemiek Walenkamp
HDHendrikus Jan Dubbink
Hendrikus Jan Dubbink
LBL. V. Beerepoot
L. V. Beerepoot
MBMartin J. Van Den Bent
Martin J. Van Den Bent
INTRODUCTION: Treatment options for recurrent glioblastoma remain limited, with only modest activity of second line chemotherapy. Despite the absence of well controlled trials, bevacizumab is widely used for recurrent glioblastoma. Nonetheless, it remains unclear if the high response rates observed after treatment with bevacizumab translate into an overall survival (OS) benefit. We report the first randomized phase II trial on bevacizumab in recurrent glioblastoma with a control arm without bevacizumab. METHODS: This was multicenter phase II study conducted in 14 Dutch sites. Patients with a first recurrence of a glioblastoma after chemo-irradiation with temozolomide were randomized between treatment with oral lomustine 110 mg/m2 once every 6 weeks, with bevacizumab 10 mg/kg once every 2 weeks intravenously or with the combination lomustine 110 mg/m2 every 6 weeks and bevacizumab 10 mg/kg every 2 weeks. Response was assessed using the RANO criteria. Primary endpoint was OS at 9 months. A safety analysis was planned after the first ten patients completed two cycles of 6 weeks in the combination arm. RESULTS: 153 patients were randomized, of which 148 were eligible. After the safety analysis the lomustine dosage in the combination arm was reduced to 90 mg/m2 because of thrombocytopenia, resulting in bevacizumab dose delays. After reduction the treatment in the combination arm was well tolerated. The percentage 9 month OS (95% confidence interval) was 43% (29, 57) in the lomustine arm, 38% (25, 51) in the bevacizumab arm, and 59% (43, 72) in the bevacizumab/lomustine 90 arm. Response rates were 35-40% for bevacizumab treated patients, and 5% in the lomustine single agent arm. CONCLUSION: This study does not show a meaningful OS at 9 months after treatment with bevacizumab alone. However, the results of combination therapy of bevacizumab with lomustine met the prespecified criterion for further phase III studies. AKNOWLEDGMENTS: This study was supported by an unrestricted grant from Roche Nederland bv. The study was also supported by grant nr DDHK 2010-4678 from the ‘KWF Kankerbestrijding’ (Dutch Cancer Society).